Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

• Anna Kalff,
• Tiffany Khong,
• Malarmathy Ramachandran,
• P Joy Ho,
• Peter Mollee,
• James D’Rozario,
• Kerry Taylor,
• Jane Estell,
• Sam Norton,
• Roslyn Kemp,
• Andrew J. Mitchell,
• John Reynolds,
• Nola Kennedy,
• Hang Quach,
• Andrew Spencer

Affiliations

Anna Kalff

Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital‐Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victoria

Tiffany Khong

Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital‐Monash University, Melbourne, Victoria

Malarmathy Ramachandran

Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital‐Monash University, Melbourne, Victoria

P Joy Ho

Royal Prince Alfred Hospital, Sydney

Peter Mollee

Princess Alexandra Hospital and University of Queensland, Brisbane

James D’Rozario

The Canberra Hospital, Canberra

Kerry Taylor

Icon Cancer Centre, Brisbane

Jane Estell

Concord Repatriation General Hospital, University of Sydney, Sydney

Sam Norton

Nanix Ltd., Dunedin, New Zealand; Department of Microbiology and Immunology, University of Otago

Roslyn Kemp

Department of Microbiology and Immunology, University of Otago

Andrew J. Mitchell

Materials Characterisation and Fabrication Platform, Department of Chemical Engineering, University of Melbourne

John Reynolds

Department of Epidemiology and Preventive Medicine, Alfred Health – Monash University, Melbourne, Victoria

Nola Kennedy

Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria

Hang Quach

Faculty of Medicine, University of Melbourne, St Vincent’s Hospital Melbourne, Australia [on behalf of The Australasian Leukaemia and Lymphoma Group (ALLG)]

Andrew Spencer

Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital‐Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victoria